Based on these data, the authors proposed that dedifferentiated breast cancer cells upregulate MDR-related genes through PERK–NRF2 signaling, while targeting this pathway might increase the sensitivity of poorly differentiated tumors refractory to anticancer drugs treatment. Here, NFE2L2 is linked to breast cancer.